Leukocyte Biology Section, National Heart and Lung Institute, Imperial College, London, UK.
Blood. 2012 Oct 4;120(14):2787-95. doi: 10.1182/blood-2011-09-378174. Epub 2012 May 31.
It has previously been reported that VEGF-A stimulates megakaryocyte (MK) maturation in vitro. Here we show that treatment of mice with the isoform VEGF-A(165) resulted in a significant increase in circulating numbers of platelets. Using specific VEGFR1 and VEGFR2 blocking mAbs and selective VEGFR1 and 2 agonists, PlGF-2 and VEGF-E, respectively, we show directly that stimulation of VEGFR1, but not VEGFR2, increases circulating platelet numbers in vivo. Using flow cytometric analysis of harvested MKs, we show that while PlGF does not change the absolute numbers of MKs present in the bone marrow and the spleen, it increases both their maturation and cell-surface expression of CXCR4 in the bone marrow. Histology of the bone marrow revealed a redistribution of MKs from the endosteal to the vascular niche in response to both VEGF-A(165) and PlGF-2 treatment in vivo. Antagonism of CXCR4 suppressed both the VEGFR1-stimulated redistribution of megakyocytes within the bone marrow compartment and the VEGF-A(165)-induced thrombocytosis. In conclusion, we define a novel proinflammatory VEGFR1-mediated pathway that stimulates the maturation and up-regulation of CXCR4 on megakaryocytes, leading to their redistribution within the bone marrow environment, thereby enhancing platelet production in vivo.
先前有报道称 VEGF-A 在体外刺激巨核细胞 (MK) 成熟。在这里,我们表明,用 VEGF-A(165) 异构体治疗小鼠会导致循环血小板数量显著增加。使用特异性 VEGFR1 和 VEGFR2 阻断 mAb 和选择性 VEGFR1 和 2 激动剂 PlGF-2 和 VEGF-E,我们直接表明刺激 VEGFR1 而不是 VEGFR2 会增加体内循环血小板数量。通过对收获的 MKs 进行流式细胞术分析,我们表明 PlGF 不会改变骨髓和脾脏中存在的 MK 的绝对数量,但会增加它们在骨髓中的成熟度和细胞表面 CXCR4 的表达。骨髓组织学显示,MK 从骨内膜重新分布到血管龛,以响应体内 VEGF-A(165) 和 PlGF-2 治疗。CXCR4 拮抗剂抑制了 VEGFR1 刺激的骨髓腔内巨核细胞的重新分布以及 VEGF-A(165) 诱导的血小板增多症。总之,我们定义了一种新的促炎 VEGFR1 介导的途径,该途径刺激巨核细胞的成熟和 CXCR4 的上调,导致其在骨髓环境中的重新分布,从而增强体内血小板生成。